secwatch / observer
8-K filed June 11, 2026, 5:19 PM ET ticker OCGN CIK 0001372299
leadership confidence high sentiment neutral materiality 0.50

Ocugen appoints Mohamed Genead as permanent Chief Medical Officer; shareholders elect directors and approve say-on-pay

Ocugen, Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Ocugen, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers at the 2026-06-11 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2026-06-11
Exact text from the filing
(c) Proposal 3 - Approval, on an advisory basis, of the compensation of the Company’s named executive officers. The stockholders voted to approve, on an advisory basis, the compensation of the Company’s named executive officers, as follows: Votes For Votes Against Abstentions Broker Non-Votes 49,968,948 13,245,090 1,505,123 74,908,914
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Ocugen, Inc. shareholders approved Election of Two Class III Directors at the 2026-06-11 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-06-11
Exact text from the filing
On June 11, 2026, Ocugen, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") virtually at 8:00 a.m. ET. At the Annual Meeting, a total of 139,628,075 shares of the Common Stock were represented virtually or by proxy. The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the Annual Meeting on June 11, 2026: (a) Proposal 1 - Election of Two Class III Directors. The stockholders elected Kirsten Castillo, MBA, and Satish Chandran, Ph.D. to the Board of Directors of the Company (the "Board") to serve as a director until the 2029 Annual Meeting of Stockholders and until their respective successor, if any, is elected and qualified, or until their earlier death, resignation, retirement, disqualification, or other removal, as follows: Name For Withheld Broker Non-Votes Kirsten Castillo, MBA 56,242,944 8,476,217 74,908,914 Satish Chandran, Ph.D. 62,604,983 2,114,178 74,908,914
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Ocugen, Inc. shareholders approved Approval, on an advisory basis, of the preferred frequency of future advisory votes on the compensation of the Company’s named executive officers at the 2026-06-11 meeting.

Proposal
say on pay frequency
Outcome
passed
Meeting
2026-06-11
Exact text from the filing
(d) Proposal 4 - Approval, on an advisory basis, of the preferred frequency of future advisory votes on the compensation of the Company’s named executive officers . The stockholders voted to approve, on an advisory basis, a preferred frequency of “one year” for future advisory votes on the compensation of the Company’s named executive officers, as follows: Votes For 1 Year Votes For 2 Years Votes For 3 Years Abstentions Broker Non-Votes 57,545,540 1,584,772 3,520,522 2,068,327 74,908,914
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Ocugen, Inc. shareholders approved Ratification of Independent Registered Public Accountant at the 2026-06-11 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-06-11
Exact text from the filing
(b) Proposal 2 - Ratification of Independent Registered Public Accountant . The ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year, as follows: Votes For Votes Against Abstentions Broker Non-Votes 136,784,245 1,002,550 1,841,280 -
View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Ocugen, Inc. filing history →

Source: SEC EDGAR
accession 0001104659-26-073015
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.